Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling

Neurobiology of Disease

Volumn 39, Issue 1, 2010, Pages 98-104

  Cilia, Roberto ^a,b,c   Ko, Ji Hyun ^a,b   Cho, Sang Soo ^a,b   van Eimeren, Thilo ^a,b   Marotta, Giorgio ^d   Pellecchia, Giovanna ^a,b   Pezzoli, Gianni ^c   Antonini, Angelo ^c,e,f   Strafella, Antonio P ^a,b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c PARKINSON INSTITUTE   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e IRCCS SAN CAMILLO HOSPITAL   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

Addiction; Dopamine transporter; Impulse control disorders; Neuroimaging; Parkinson's disease; Pathological gambling; SPECT; Statistical Parametric Mapping; Ventral striatum

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER;

ADULT; ARTICLE; BRAIN FUNCTION; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; IMAGE ANALYSIS; LIMBIC SYSTEM; MALE; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PRIORITY JOURNAL;

AGED; BASAL GANGLIA; BINDING, COMPETITIVE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GAMBLING; HUMANS; MALE; MIDDLE AGED; NEOSTRIATUM; PARKINSON DISEASE; PROTEIN BINDING; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 77952955623     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.03.013     Document Type: Article

References (47)

1. Abler B., Hahlbrock R., Unrath A., Grön G., Kassubek J. At-risk for pathological gambling: imaging neural reward processing under chronic dopamine agonists. Brain 2009, 132(Pt 9):2396-2402.
2. Adams J.R., van Netten H., Schulzer M., Mak E., Mckenzie J., Strongosky A., Sossi V., Ruth T.J., Lee C.S., Farrer M., Gasser T., Uitti R.J., Calne D.B., Wszolek Z.K., Stoessl A.J. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005, 128(Pt 12):2777-2785.
3. Ahlskog J.E., Uitti R.J., O'Connor M.K., Maraganore D.M., Matsumoto J.Y., Stark K.F., Turk M.F., Burnett O.L. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov. Disord. 1999, 14(6):940-946.
4. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
5. Antonini A., Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. Drug Saf. 2009, 32(6):475-488.
6. Bódi N., Kéri S., Nagy H., Moustafa A., Myers C.E., Daw N., Dibó G., Takáts A., Bereczki D., Gluck M.A. Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain 2009, 132(Pt 9):2385-2395.
7. Booij J., Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(2):424-438.
8. Booij J., Tissingh G., Boer G.J., Speelman J.D., Stoof J.C., Janssen A.G., et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1997, 62:133-140.
9. Brewer J.A., Potenza M.N. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem. Pharmacol. 2008, 75(1):63-75.
10. Chatfield C., Collins A.J. Introduction to Multivariate Analysis 1980, Chapman and Hall.
11. Cilia R., Siri C., Marotta G., Isaias I.U., De Gaspari D., Canesi M., Pezzoli G., Antonini A. Functional abnormalities underlying pathological gambling in Parkinson disease. Arch. Neurol. 2008, 65:1604-1611.
12. Colloby S.J., O'Brien J.T., Fenwick J.D., Firbank M.J., Burn D.J., McKeith I.G., Williams E.D. The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease. Neuroimage 2004, 23(3):956-966.
13. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. l-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 2003, 41(11):1431-1441.
14. Davie M. Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J. Neuropsychiatry Clin. Neurosci. 2007, 19(4):473-474.
15. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N. Engl. J. Med. 2001, 345:956-963. Deep-Brain Stimulation for Parkinson's Disease Study Group.
16. Dreher J.C., Kohn P., Kolachana B., Weinberger D.R., Berman K.F. Variation in dopamine genes influences responsivity of the human reward system. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(2):617-622.
17. Driver-Dunckley E.D., Noble B.N., Hentz J.G., Evidente V.G., Caviness J.N., Parish J., Krahn L., Adler C.H. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin. Neuropharmacol. 2007, 30(5):249-255.
18. Evans A.H., Pavese N., Lawrence A.D., Tai Y.F., Appel S., Doder M., Brooks D.J., Lees A.J., Piccini P. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann. Neurol. 2006, 59:852-858.
19. Falhammar H., Yarker J.Y. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med. J. Aust. 2009, 190(2):97.
20. Forbes E.E., Brown S.M., Kimak M., Ferrell R.E., Manuck S.B., Hariri A.R. Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity. Mol. Psychiatry 2009, 14(1):60-70.
21. Franklin T.R., Lohoff F.W., Wang Z., Sciortino N., Harper D., Li Y., Jens W., Cruz J., Kampman K., Ehrman R., Berrettini W., Detre J.A., O'Brien C.P., Childress A.R. DAT genotype modulates brain and behavioral responses elicited by cigarette cues. Neuropsychopharmacology 2009, 34(3):717-728.
22. Haile C.N., Kosten T.R., Kosten T.A. Genetics of dopamine and its contribution to cocaine addiction. Behav. Genet. 2007, 37(1):119-145.
23. Holman A.J. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J. Gambl. Stud. 2009, 25(3):425-431.
24. Jones S., Gainetdinov R., Jaber M., Giros B., Wightman R., Caron M. Profound neuronal plasticity in response to inactivation of the dopamine transporter. PNAS 1998, 95:4029-4034.
25. Kas A., Payoux P., Habert M.O., Malek Z., Cointepas Y., El Fakhri G., Chaumet-Riffaud P., Itti E., Remy P. Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images. J. Nucl. Med. 2007, 48(9):1459-1467.
26. Klein, T.A., Neumann, J., Reuter, M., Hennig, J., von Cramon, D.Y., Ullsperger, M., 2007. Genetically determined differences in learning from errors. Science 318 (5856), 1642-1645.
27. Kreek M.J., Nielsen D.A., Butelman E.R., LaForge K.S. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat. Neurosci. 2005, 8(11):1450-1457.
28. Laruelle M., Wallace E., Seibyl J.P., Baldwin R.M., Zea Ponce Y., Zoghbi S.S., Neumeyer J.L., Charney D.S., Hoffer P.B., Innis R.B. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J. Cereb. Blood Flow Metab. 1994, 14:982-994.
29. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., Wudel J., Pal P.K., de la Fuente-Fernandez R., Calne D.B., Stoessl A.J. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 2000, 47:493-503.
30. Lee J.Y., Lee E.K., Park S.S., Lim J.Y., Kim H.J., Kim J.S., Jeon B.S. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov. Disord. 2009, 24(12):1803-1810.
31. Lesieur H.R., Blume S.B. The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am. J. Psychiatry 1987, 144:1184-1188.
32. Lind P.A., Eriksson C.J., Wilhelmsen K.C. Association between harmful alcohol consumption behavior and dopamine transporter (DAT1) gene polymorphisms in a male Finnish population. Psychiatr. Genet. 2009, 19(3):117-125.
33. Muramatsu T., Higuchi S. Dopamine transporter gene polymorphism and alcoholism. Biochem. Biophys. Commun. 1995, 211:28-32.
34. Peciña S., Cagniard B., Berridge K.C., Aldridge J.W., Zhuang X. Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. J. Neurosci. 2003, 23(28):9395-9402.
35. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Brain Rev. 1993, 18:247-291.
36. Roussos P., Giakoumaki S.G., Bitsios P. Cognitive and emotional processing in high novelty seeking associated with the L-DRD4 genotype. Neuropsychologia 2009, 47:1654-1659.
37. Scherfler C., Seppi K., Donnemiller E., Goebel G., Brenneis C., Virgolini I., Wenning G.K., Poewe W. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain 2005, 128(Pt 7):1605-1612.
38. Scherfler C., Schwarz J., Antonini A., Grosset D., Valldeoriola F., Marek K., Oertel W., Tolosa E., Lees A.J., Poewe W. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov. Disord. 2007, 22(9):1229-1238.
39. Schmid B., Blomeyer D., Becker K., Treutlein J., Zimmermann U.S., Buchmann A.F., Schmidt M.H., Esser G., Banaschewski T., Rietschel M., Laucht M. The interaction between the dopamine transporter gene and age at onset in relation to tobacco and alcohol use among 19-year-olds. Addict. Biol. 2009, 14(4):489-499.
40. Shinohara M., Mizushima H., Hirano M., Shioe K., Nakazawa M., Hiejima Y., Ono Y., Kanba S. Eating disorders with binge-eating behaviour are associated with the s allele of the 3Ž-UTR VNTR polymorphism of the dopamine transporter gene. J. Psychiatry Neurosci. 2004, 29(2):134-137.
41. Sossi V., de la Fuente-Fernandez R., Schulzer M., Troiano A.R., Ruth T.J., Stoessl A.J. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann. Neurol. 2007, 62:468-474.
42. Steeves T.D., Miyasaki J., Zurowski M., Lang A.E., Pellecchia G., Van Eimeren T., Rusjan P., Houle S., Strafella A.P. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009, 132:1376-1385.
43. Tippmann-Peikert M., Park J.G., Boeve B.F., Shepard J.W., Silber M.H. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007, 68(4):301-303.
44. Troiano A.R., de la Fuente-Fernandez R., Sossi V., Schulzer M., Mak E., Ruth T.J., Stoessl A.J. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009, 72(14):1211-1216.
45. Varrone A., Sansone V., Pellecchia M.T., Amboni M., Salvatore E., De Michele G., Filla A., Barone P., Pappatà S., Salvatore M. Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(7):1343-1349.
46. Voon V., Fox S.H. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch. Neurol. 2007, 64(8):1089-1096.
47. Voon V., Fernagut P.O., Wickens J., Baunez C., Rodriguez M., Pavon N., Juncos J.L., Obeso J.A., Bezard E. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol. 2009, 8(12):1140-1149.